BioSpace News Archive

SILVER SPRING, Md., /PRNewswire/ -- Today, the U.S. Food and Drug Administration permitted marketing, with special controls, of the 23andme Personal Genome Service Pharmacogenetic Reports test as a direct-to-consumer test for providing information about genetic variants that may be associated with a patient’s ability to metabolize some medications to help inform discussions with a health care provider.

Effort Urges Individuals At-Risk for Lung Cancer to Talk to Their Doctor About Life-Saving Screening

AgaMatrix and Arcadia Group announced today a strategic partnership leveraging AgaMatrix’s proprietary blood glucose monitoring (BGM) technology for the Choice line of diabetes products marketed by Arcadia.

Direct action to stop overburdening begins at midnight

On October 31, 2018, Judge Valerie Caproni of the United States District Court for the Southern District of New York entered an Opinion and Order, as well as a Judgment, dismissing all claims raised by Platinum-Montaur Life Sciences LLC

Brookdale Senior Living Inc. today announced that Lucinda “Cindy” Baier, President and Chief Executive Officer will participate in a discussion regarding the Company at the Stephens NY Investment Conference in New York, New York on Wednesday, November 7, 2018, beginning at 7:30 a.m. Eastern Time.

Medical professional liability insurer adds 11th state as it continues its nationwide expansion

The decision allows 23andMe to report directly to customers, without a prescription, the influence their genetics have on how well they metabolize certain medications

Open Enrollment for the Affordable Care Act (ACA) health insurance marketplace opens tomorrow.

Agilent Technologies Inc. (NYSE: A) today announced the introduction of Agilent OnePGT, a genome-wide, next-generation sequencing (NGS) solution for preimplantation genetic testing (PGT).